Multicenter open-label sertraline study in adolescent outpatients with major depression

Paul J. Ambrosini, Karen Wagner, Joseph Biederman, Ira Click, Claire Tan, Josephine Elia, Joan R. Hebeler, Harris Rabinovich, James Lock, Daniel Geller

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Objective: The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD). Method: Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale. Results: By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement was maintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.

Original languageEnglish (US)
Pages (from-to)566-572
Number of pages7
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume38
Issue number5
StatePublished - 1999

Fingerprint

Sertraline
Outpatients
Depression
Major Depressive Disorder
Therapeutics
Mood Disorders
Multicenter Studies
Schizophrenia
Appointments and Schedules
Safety
Equipment and Supplies

Keywords

  • Adolescent
  • Depression
  • Pharmacotherapy
  • Rating scales
  • Sertraline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Multicenter open-label sertraline study in adolescent outpatients with major depression. / Ambrosini, Paul J.; Wagner, Karen; Biederman, Joseph; Click, Ira; Tan, Claire; Elia, Josephine; Hebeler, Joan R.; Rabinovich, Harris; Lock, James; Geller, Daniel.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 38, No. 5, 1999, p. 566-572.

Research output: Contribution to journalArticle

Ambrosini, PJ, Wagner, K, Biederman, J, Click, I, Tan, C, Elia, J, Hebeler, JR, Rabinovich, H, Lock, J & Geller, D 1999, 'Multicenter open-label sertraline study in adolescent outpatients with major depression', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 38, no. 5, pp. 566-572.
Ambrosini, Paul J. ; Wagner, Karen ; Biederman, Joseph ; Click, Ira ; Tan, Claire ; Elia, Josephine ; Hebeler, Joan R. ; Rabinovich, Harris ; Lock, James ; Geller, Daniel. / Multicenter open-label sertraline study in adolescent outpatients with major depression. In: Journal of the American Academy of Child and Adolescent Psychiatry. 1999 ; Vol. 38, No. 5. pp. 566-572.
@article{0fa31d9948444dd7909059bd8eb86883,
title = "Multicenter open-label sertraline study in adolescent outpatients with major depression",
abstract = "Objective: The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD). Method: Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale. Results: By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement was maintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.",
keywords = "Adolescent, Depression, Pharmacotherapy, Rating scales, Sertraline",
author = "Ambrosini, {Paul J.} and Karen Wagner and Joseph Biederman and Ira Click and Claire Tan and Josephine Elia and Hebeler, {Joan R.} and Harris Rabinovich and James Lock and Daniel Geller",
year = "1999",
language = "English (US)",
volume = "38",
pages = "566--572",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Multicenter open-label sertraline study in adolescent outpatients with major depression

AU - Ambrosini, Paul J.

AU - Wagner, Karen

AU - Biederman, Joseph

AU - Click, Ira

AU - Tan, Claire

AU - Elia, Josephine

AU - Hebeler, Joan R.

AU - Rabinovich, Harris

AU - Lock, James

AU - Geller, Daniel

PY - 1999

Y1 - 1999

N2 - Objective: The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD). Method: Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale. Results: By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement was maintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.

AB - Objective: The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD). Method: Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale. Results: By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement was maintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.

KW - Adolescent

KW - Depression

KW - Pharmacotherapy

KW - Rating scales

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=13044300889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13044300889&partnerID=8YFLogxK

M3 - Article

C2 - 10230188

AN - SCOPUS:13044300889

VL - 38

SP - 566

EP - 572

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 5

ER -